Recruiting Ovarian Cancer Studies in Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of...
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as RE...
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with huma...
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherap...
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer....
Belzutifan in Recurrent Clear Cell Ovarian Carcinoma
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with ovarian cancer. The name of the study drug involved in this study is: \- Belzuti...
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment wit...
About Ovarian Cancer Clinical Trials in Boston
Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.
There are currently 7 ovarian cancer clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 2,956 participants. Research is being sponsored by Regeneron Pharmaceuticals, Daiichi Sankyo, M.D. Anderson Cancer Center and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ovarian Cancer Clinical Trials in Boston — FAQ
Are there ovarian cancer clinical trials in Boston?
Yes, there are 7 ovarian cancer clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Boston?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.
Are clinical trials in Boston free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.
What ovarian cancer treatments are being tested?
The 7 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.
Data updated March 2, 2026 from ClinicalTrials.gov